Covid 19 Research using Clinical Trials (Home Page)
Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administrationWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
|
Name (Synonyms) |
Correlation |
drug616 | Community Referral as appropriate Wiki | 1.00 |
drug595 | Cognitive Behavioral Therapy Wiki | 0.71 |
Correlated MeSH Terms (3)
|
Name (Synonyms) |
Correlation |
D009771 | Obsessive-Compulsive Disorder NIH | 1.00 |
D003193 | Compulsive Personality Disorder NIH | 1.00 |
D003192 | Compulsive Behavior NIH | 1.00 |
Correlated HPO Terms (1)
|
Name (Synonyms) |
Correlation |
HP:0000722 | Obsessive-compulsive behavior HPO | 0.71 |
There is one clinical trial.
Clinical Trials
Covid-19 infection is due to SARS-CoV-2 member of the Coronavirus family represented by SARS-
and MERS-CoVwith neuronal tropism capacity for the brainstem and thalami. Dexmedetomidine
has(i) central antihypertensive (ii) sedative and (iii) neuroprotective properties and is
often used during patient recovering after mechanical ventilation withdrawal.
Dexmedetomidine administration could change the immunomodulatory profile of Covid-19 patients
and reduce inflammatory response.CAM-ICU scores and Blood samples from Covid-19 ICU patients
will be collected at 4 different timepoints (before Dexmedetomidine administration, at D2, D7
and M6) to analyse the inflammatory profile with different approaches:i) chromatin
accessibility, ii) transcriptome analysis, iii) inflammatory cytokines and chemokines levels.
NCT04413864 SARS-CoV 2 Other: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration
Primary Outcomes
Measure: Change of inflammatory cytokines concentration (mmol / L) in Covid19 + patients from Baseline at 6 months Time: Month6
Secondary Outcomes
Measure: Change of interrelationship between inflammation (cytokines levels) and ICU delirium in Covid19 + patient from Baseline at 6 months Time: Month6
Measure: Modification in inflammatory genes expressed (expressed / non expressed) in PBMC between Baseline and M6 Time: Month6
Measure: Change in quantity of chromatine's openings (chromatin accessibility profiles) in ICU patient recovering from covid19 infection Time: Day2, Month6
Measure: Change in genes expression in Covid-19 patient with delirium in ICU between Day2 and Month6 Time: Day2, Month6
No related HPO nodes (Using clinical trials)